Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, L., MiRNA-based Lifespan extension therapy: NRF2 may prolong mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 23/April/2014, 6.27 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Significance: It has been shown earlier that angiotensin II type I receptor (AT1R) antagonist prolongs mammalian life span. This study suggests, for the first time, that NRF2, by increasing the expression of their target gene, they may suppress the expression of AT1R. And, thereby, they may (1) decrease blood pressure; and (2) extend the lifespan of an individual. Thus, pharmacological formulations encompassing “NRF2 activators” may be used to extend the life-span of an individual.
Undisclosed information: How NRF2 suppresses the expression of angiotensin II type I receptor (AT1R)
